PMID- 9051698
OWN - NLM
STAT- MEDLINE
DCOM- 19970515
LR  - 20181130
IS  - 1043-6618 (Print)
IS  - 1043-6618 (Linking)
VI  - 34
IP  - 3-4
DP  - 1996 Sep-Oct
TI  - Altered uterine sensitivity to oxytocin and prostaglandin F2 alpha in 
      dimethylbenz(a)anthracene (DMBA)-induced rat mammary carcinoma: the effects of 
      tamoxifen and/or recombinant human interferon alpha 2b therapy.
PG  - 99-103
AB  - This study aimed to investigate the long-term toxicity of a preventive regimen of 
      tamoxifen (TAM) and recombinant human interferon alpha 2b (rHuIFN alpha 2b) on 
      the uterine responsiveness of tumour-bearing rats. The experimental tumour was 
      induced by dimethylbenz(a)anthracene (DMBA) in virgin female albino rats and the 
      therapy was started two months after carcinogen administration. The acute effect 
      of DMBA on the uterine sensitivity was also assessed 24 h post-carcinogen. The 
      uterotonic potentials of oxytocin and prostaglandin F2 alpha (PGF2 alpha) were 
      markedly reduced in the control tumour-bearing group as compared to the normal 
      one. Similarly, acute DMBA administration showed reduced uterine sensitivity to 
      both agents. Treatment with either TAM or combined TAM/rHuIFN alpha 2b did not 
      affect the uterine response to either oxytocin or PGF2 alpha, while rHuIFN alpha 
      2b increased the uterine sensitivity to oxytocin but not to PGF2 alpha. These 
      data indicate that the carcinogenic agent per se and the presence of tumour 
      reduce the contractile response in the rat uterus to oxytocic agents. Moreover, 
      combined TAM/rHuIFN alpha 2b does not markedly affect the uterine sensitivity in 
      DMBA-induced mammary carcinoma-bearing rats.
FAU - Badary, O A
AU  - Badary OA
AD  - Pharmacology Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
FAU - Agha, A M
AU  - Agha AM
FAU - el-Sayed, E S
AU  - el-Sayed ES
FAU - Hamada, F M
AU  - Hamada FM
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Carcinogens)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 50-56-6 (Oxytocin)
RN  - 57-97-6 (9,10-Dimethyl-1,2-benzanthracene)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - 9,10-Dimethyl-1,2-benzanthracene
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Antineoplastic Agents, Hormonal/pharmacology
MH  - Carcinogens
MH  - Dinoprost/*pharmacology
MH  - Female
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/pharmacology
MH  - Mammary Neoplasms, Experimental/*chemically induced/pathology
MH  - Oxytocin/*pharmacology
MH  - Rats
MH  - Recombinant Proteins
MH  - Tamoxifen/pharmacology
MH  - Uterus/*drug effects
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - S1043-6618(96)90071-7 [pii]
AID - 10.1006/phrs.1996.0071 [doi]
PST - ppublish
SO  - Pharmacol Res. 1996 Sep-Oct;34(3-4):99-103. doi: 10.1006/phrs.1996.0071.